Literature DB >> 27247757

Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential.

Madeleine Duvic1, Mark Evans2, Casey Wang3.   

Abstract

Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma (CTCL). We review the mechanism of action of mogamulizumab and its role in treating CTCL. We also discuss the results of major clinical trials.

Entities:  

Keywords:  cutaneous T-cell lymphoma; mogamulizumab; peripheral T-cell lymphoma

Year:  2016        PMID： 27247757      PMCID： PMC4872175          DOI： 10.1177/2040620716636541

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  19 in total

1.  Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.

Authors:  Nobuhiro Ohno; Seiichiro Kobayashi; Tomohiro Ishigaki; Koichiro Yuji; Masayuki Kobayashi; Koota Sato; Nobukazu Watanabe; Arinobu Tojo; Kaoru Uchimaru
Journal:  Br J Haematol       Date:  2013-09-03       Impact factor: 6.998

2.  CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis.

Authors:  Makoto Sugaya; Sohshi Morimura; Hiraku Suga; Makiko Kawaguchi; Tomomitsu Miyagaki; Hanako Ohmatsu; Hideki Fujita; Shinichi Sato
Journal:  J Dermatol       Date:  2015-03-26       Impact factor: 4.005

Review 3.  Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.

Authors:  Berna Bozkurt Duman; Berksoy Sahin; Melek Ergin; Birol Guvenc
Journal:  Med Oncol       Date:  2011-07-31       Impact factor: 3.064

4.  The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.

Authors:  Toyohide Shinkawa; Kazuyasu Nakamura; Naoko Yamane; Emi Shoji-Hosaka; Yutaka Kanda; Mikiko Sakurada; Kazuhisa Uchida; Hideharu Anazawa; Mitsuo Satoh; Motoo Yamasaki; Nobuo Hanai; Kenya Shitara
Journal:  J Biol Chem       Date:  2002-11-08       Impact factor: 5.157

5.  Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.

Authors:  Xiao Ni; Jeffrey L Jorgensen; Meghali Goswami; Pramoda Challagundla; William K Decker; Youn H Kim; Madeleine A Duvic
Journal:  Clin Cancer Res       Date:  2014-11-05       Impact factor: 12.531

6.  Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.

Authors:  Toshihiko Ishii; Takashi Ishida; Atae Utsunomiya; Atsushi Inagaki; Hiroki Yano; Hirokazu Komatsu; Shinsuke Iida; Kazunori Imada; Takashi Uchiyama; Shiro Akinaga; Kenya Shitara; Ryuzo Ueda
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 12.531

7.  Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.

Authors:  Asahi Ito; Takashi Ishida; Hiroki Yano; Atsushi Inagaki; Susumu Suzuki; Fumihiko Sato; Hisashi Takino; Fumiko Mori; Masaki Ri; Shigeru Kusumoto; Hirokazu Komatsu; Shinsuke Iida; Hiroshi Inagaki; Ryuzo Ueda
Journal:  Cancer Immunol Immunother       Date:  2008-12-02       Impact factor: 6.968

8.  Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.

Authors:  Takashi Ishida; Atae Utsunomiya; Shinsuke Iida; Hiroshi Inagaki; Yoshifusa Takatsuka; Shigeru Kusumoto; Genji Takeuchi; Shigeki Shimizu; Masato Ito; Hirokazu Komatsu; Atsushi Wakita; Tadaaki Eimoto; Kouji Matsushima; Ryuzo Ueda
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

9.  Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.

Authors:  Kelley A Vidulich; Rakhshandra Talpur; Roland L Bassett; Madeleine Duvic
Journal:  Int J Dermatol       Date:  2009-03       Impact factor: 2.736

10.  Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL.

Authors:  Takeshi Tsuchiya; Koichi Ohshima; Kennosuke Karube; Takahiro Yamaguchi; Hiroaki Suefuji; Makoto Hamasaki; Chika Kawasaki; Junji Suzumiya; Masao Tomonaga; Masahiro Kikuchi
Journal:  Blood       Date:  2003-09-04       Impact factor: 22.113
View more
  9 in total

Review 1.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

Review 2.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

3.  Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.

Authors:  Ting Zhang; Jing Sun; Jinying Li; Yunuo Zhao; Tao Zhang; Ruoning Yang; Xuelei Ma
Journal:  BMC Cancer       Date:  2021-05-26       Impact factor: 4.430

Review 4.  The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity.

Authors:  Stefanie Scheu; Shafaqat Ali; Christina Ruland; Volker Arolt; Judith Alferink
Journal:  Int J Mol Sci       Date:  2017-11-02       Impact factor: 5.923

5.  Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy.

Authors:  Taku Fujimura; Kayo Tanita; Yota Sato; Yumi Kambayashi; Sadanori Furudate; Akira Tsukada; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2018-01-16

Review 6.  Mechanisms of Regulation of the Chemokine-Receptor Network.

Authors:  Martin J Stone; Jenni A Hayward; Cheng Huang; Zil E Huma; Julie Sanchez
Journal:  Int J Mol Sci       Date:  2017-02-07       Impact factor: 5.923

7.  Management Strategies for Mycosis Fungoides in India.

Authors:  Tanumay Raychaudhury
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

Review 8.  Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies.

Authors:  Anagha Deshpande; Javier Munoz
Journal:  Front Oncol       Date:  2022-09-12       Impact factor: 5.738

9.  Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.

Authors:  Steven Horwitz; Pier Luigi Zinzani; Martine Bagot; Youn H Kim; Alison J Moskowitz; Pierluigi Porcu; Karen Dwyer; Wei Sun; Fiona M Herr; Julia Scarisbrick
Journal:  Leuk Lymphoma       Date:  2021-07-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.